Establishment of a Radiogenomics Consortium

Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
Radiotherapy and Oncology (Impact Factor: 4.36). 04/2010; 94(1):117–118. DOI: 10.1016/j.radonc.2009.12.007
7 Reads
    • "There is too much discovery and too little validation that involves assessment in multiple independent cohorts and assessment of reproducibility. A consortium approach can increase the size and quality of cohorts studied, for example the Radiogenomics Consortium [13] that is underpinning the discovery of genetic markers of individual radiosensitivity [8]. The development of guidelines for reporting radiotherapy biomarker studies is also needed [14]. "

    Clinical Oncology 07/2015; 27(10). DOI:10.1016/j.clon.2015.06.021 · 3.40 Impact Factor
    • "Information from GWAS of other phenotypes suggest that the allelic architecture underlying radiosensitivity will include a spectrum ranging from rare, highly penetrant to low-risk common alterations [68]. The increasing recognition that GWAS must include tens or even hundreds of thousands of patients [56e68] led to the establishment of a radiogenomics consortium in 2009 [69]. The consortium created a vital link between existing collaborative groups [64,66,70e73]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is considerable variation in the level of toxicity patients experience for a given dose of radiotherapy, which is associated with differences in underlying individual normal tissue radiosensitivity. A number of syndromes have a large effect on clinical radiosensitivity, but these are rare. Among non-syndromic patients, variation is less extreme, but equivalent to a ±20% variation in dose. Thus, if individual normal tissue radiosensitivity could be measured, it should be possible to optimise schedules for individual patients. Early investigations of in vitro cellular radiosensitivity supported a link with tissue response, but individual studies were equivocal. A lymphocyte apoptosis assay has potential, and is currently under prospective validation. The investigation of underlying genetic variation also has potential. Although early candidate gene studies were inconclusive, more recent genome-wide association studies are revealing definite associations between genotype and toxicity and highlighting the potential for future genetic testing. Genetic testing and individualised dose prescriptions could reduce toxicity in radiosensitive patients, and permit isotoxic dose escalation to increase local control in radioresistant individuals. The approach could improve outcomes for half the patients requiring radical radiotherapy. As a number of patient- and treatment-related factors also affect the risk of toxicity for a given dose, genetic testing data will need to be incorporated into models that combine patient, treatment and genetic data. Copyright © 2015. Published by Elsevier Ltd.
    Clinical Oncology 07/2015; 27(10). DOI:10.1016/j.clon.2015.06.013 · 3.40 Impact Factor
  • Source
    • "Radiogenomics is a multi-disciplinary scientific research field aiming to link human genomic variability to a cancer patient's likelihood of developing toxicity following radiotherapy [1]. Over 80 publications to date reported results of studies investigating correlations between genetic markers and radiotherapy toxicity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Unlabelled: Normal-tissue adverse effects following radiotherapy are common and significantly affect quality of life. These effects cannot be accounted for by dosimetric, treatment, or demographic factors alone, and evidence suggests that common genetic variants are associated with radiotherapy adverse effects. The field of radiogenomics has evolved to identify such genetic risk factors. Radiogenomics has two goals: (i) to develop an assay to predict which patients with cancer are most likely to develop radiation injuries resulting from radiotherapy, and (ii) to obtain information about the molecular pathways responsible for radiation-induced normal-tissue toxicities. This review summarizes the history of the field and current research. Significance: A single-nucleotide polymorphism–based predictive assay could be used, along with clinical and treatment factors, to estimate the risk that a patient with cancer will develop adverse effects from radiotherapy. Such an assay could be used to personalize therapy and improve quality of life for patients with cancer.
    Cancer Discovery 01/2014; 4(2). DOI:10.1158/2159-8290.CD-13-0197 · 19.45 Impact Factor
Show more

Similar Publications